



## 2020 Market Analysis of Maternal Fetal and Neonatal Medicine

Aziz Koleilat

*Pediatric specialization & Founder, Department of Pediatrics, Berbir, Makassed & Mother and Child Hospitals, Beirut, Lebanon, E-mail: azizk05@yahoo.com*

Maternal, fetal-neonatal medicine is an international platform for presenting research about diagnosis, prevention, and management of fetal diseases, exchanging ideas about it and thus, contributes to the dissemination of knowledge in maternal, fetal-neonatal medicine, for the benefit of both the academic and business. We bring together industry executives, maternal, fetal-neonatal pharma and Health care sectors making the conference a perfect platform to network, share views and knowledge through interactive discussions.

[Maternal, fetal-neonatal medicine](#) procedures vary from market to market. Most companies view Maternal, fetal-neonatal procedures as preventive care and therefore do not cover them, and many have historically had refuse for congenital conditions as well. Still, in markets where these conditions are covered, costs generally do not exceed USD \$35,000. That is lower than the costs incurred to treat congenital conditions even in just the first year of life. It may, therefore, be more cost-effective to treat conditions such as fetal lung and heart defects and spinal bifida in utero, as doing so can save costs compared to postnatal procedures.

### Products Manufactured by the Industry Related Maternal, Fetal-neonatal Medicine Research and its Market Value:

According to a present market research report "[maternal, fetal Monitoring Market](#) by Product (Ultrasound, Electrodes, Uterine Contraction, Doppler, Electronic Fetal Monitors, and Telemetry), Application (Antepartum, Intrapartum), Portability, Method (Invasive), End User (Hospital, Clinics) - Forecast to 2018", published by Markets and Markets, the global Fetal Monitoring Market is expected to reach \$2,947.4 Million by 2019 from \$1,988.8 Million in 2017, at a CAGR of 6.9% from 2015 to 2019.

List of drugs manufactured for Infants: Ampicillin, Ativan, BiCitra, Dexamethasone, Epinephrine, Fentanyl, Fluconazole, Rocuronium.

### Market Growth of Maternal, Fetal-neonatal Medicine in the Past and Upcoming Years:

Reports state that the global maternal, fetal-neonatal medicine market divided into global NICU equipment market, global labor and delivery equipment market, and global other labor & delivery equipment & NICU equipment market over the forecasted period (2014-2019). The global NICU equipment market was worth \$1.5 billion in 2015; growing at a steady pace to reach \$1.8 billion in 2018. The global labor and delivery equipment market that primarily consists of fetal monitors is valued at \$613 million in 2015; growing to reach \$796 million in 2017. The global other labor & delivery equipment & NICU equipment market that mainly having respiratory assistance devices, monitoring equipment, and delivery systems is worth over \$2.2 billion in 2014; growing to reach \$3.2 billion in 2019.

Monitoring procedures are important for the evaluation of the clinical state of patients and to assess changes in their conditions, thus providing necessary treatments on time. Both these two objectives can be achieved by introducing technology, thus, allowing accurate classification and extraction of useful diagnostic information. It has been indicated that the computation of different indices on FHRV signals, either linear or nonlinear, gives helpful indications to describe pathophysiological mechanisms involved in the cardiovascular and neural system controlling the fetal heart. As a more contribution, also wearable systems for fetal ECG recording could provide new technological solutions improving the quality and usability of prenatal monitoring. These technological advancements provide a feasible environment for the growth of this market in the

future. Additionally, increasing incidence of premature birth and growing government initiatives in developing countries regarding fetal care are further augmenting the market growth.



According to the recent analysis of Reports and Data, the global Neonatal and Fetal (Labor & Delivery) Care Market was valued at USD 6.39 billion in 2018 and is expected to reach USD 9.80 billion by the year 2026, at a CAGR of 5.5%. Maternity care and infant safety are top healthcare priorities in developed as well as developing nations. With technological and infrastructural advancements in healthcare across the globe, the market for fetal and infant healthcare is on rise. The efficacy of the neonatal products & services is a crucial factor for the safety during childbirth. According to report, globally every year more than one out of seven births (20 million babies worldwide) are born with low birth weight.

The Asia Pacific region is expected to grow at a considerably higher rate during the forecast period owing to aspects, such as high birth rate in some Asia Pacific countries, such as India & China along with rising awareness programs for the improvement of fetal care & neonatal care.

Neonatal care service in Malaysia is almost entirely publicly funded and has expanded substantially over the last 20 years. Perinatal and neonatal outcomes have also improved considerably in the same period. Prior to 1995, the perinatal mortality rates (PMR) ranged from 12.6 to 25.4 per 1000 births depending on the hospital and region served. The PMR has since dropped to 9.7 per 1000 births in 1999.3 Similarly, the neonatal mortality

rate has shown a gradual decline from 14.2 per 1000 live births (LB) in 1980,4 to 8.5 per 1000 LB in 1990 and 5.1 per 1000 LB in 1998.5 The outcome of very low birth weight (VLBW) babies has also been evaluated in a national study.6 A cohort of VLBW babies was enrolled in 1993 and followed up till 1996. The survival rate was 62.6% in 1993 and 69.3% in 1996. Neurodevelopmental outcome at 2 years of age was assessed for 77 survivors out of a cohort of 150 VLBW infants born in 1993. The mean general quotient on the Griffith's developmental scale of the 77 infants was 94 as compared 104 in a control group. Functionally 70.2% were normal, 23.3% had mild handicap, 1.3% moderate, 2.5% severe handicap and 2.5% multiple severe handicap.

The worldwide market for women's wellbeing therapeutics will develop from about \$33.0 billion in 2015 to almost \$40.6 billion by 2020, with a compound annual growth rate (CAGR) of 4.2% for the time of 2015-2020. The advanced research on investigation of women health care has stated that the global women healthcare market is elide upon to achieve USD 5.13 billion by 2025. The Global Women's Health Market was evaluated to be 30.88bn of every 2016 and anticipated that would reach more than 51.3bn by 2025 at a CAGR of 5.85% as assessed by various autonomous research firms.

#### Universities Associated with maternal fetal neonatal medicine



**Contact:**  
**Anna Gill**  
 Program Manager  
 PCOS Congress 2019  
 47 Churchfield Road  
 London, W3 6AY, United Kingdom  
 Tel: +1-201-380-5561